Handbook of therapeutic antibodies

Volume I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE Selection strategies I: Monoclonal Antibodies Selection strategies II: Antibody Phage Display Selection strategies III: Transgenic Mice Bioinformatic Tools for Antibody Engineering Molecular Engineering I: Humanization Molecular Engineering II: Affinity Maturation Molecular Engineering III: Fc Engineering PART II: THE WAY INTO THE CLINIC Production and Downstream Processing Pharmaceutical Formulation and Clinical Application Immunogenicity of Antibody Therapeutics Regulatory Considerations Intellectual Property Issues Volume II: Emerging Developments PART III: BEYOND IGG: MODIFIED ANTIBODIES Immunoscintigraphy and Radioimmunotherapy Bispecific Antibodies Immunotoxins / Targeted RNases PART IV: EMERGING CONCEPTS Automation of Selection and Engineering Emerging Technologies for Antibody Selection Emerging Alternative Production Systems Non-Antibody Scaffolds Emerging Therapeutic Concepts I: ADEPT Emerging Therapeutic Concepts II: Nanotechnology Emerging Therapeutic Concepts III:Cell-bound antibodies Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies PART V: ONGOING CLINICAL STUDIES: Antibodies in Phase I/II/III: Cancer Therapy Antibodies in Phase I/II/III: Targeting TNF VOLUME III: APPROVED THERAPEUTICS Adalimumab (Humira) Alemtuzumab (Mabcampath) Bevacizumab (Avastin) Cetuximab (Erbitux) Efalizumab (Raptiva) Fanolesomab/Technetium99m (Neutrospec) Gemtuzumab Ozogamicin (Mylotarg) Infliximab (Remicade) Muromonab (Orthoclone) Natalizumab (Tysabri) Omalizumab (Xolair) Palivizumab (Synagis) Rituximab (Rituxan) Trastuzumab (Herceptin) Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab